2041 related articles for article (PubMed ID: 25625927)
21. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
Amedei A; Niccolai E; Prisco D
Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models.
Aurisicchio L; Peruzzi D; Koo G; Wei WZ; La Monica N; Ciliberto G
Hum Gene Ther; 2014 Feb; 25(2):121-31. PubMed ID: 24195644
[TBL] [Abstract][Full Text] [Related]
23. [Anti-HER2 vaccines: The HER2 immunotargeting future?].
Ladjemi MZ; Jacot W; Pèlegrin A; Navarro-Teulon I
Pathol Biol (Paris); 2011 Jun; 59(3):173-82. PubMed ID: 19481373
[TBL] [Abstract][Full Text] [Related]
24. DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma.
Joseph-Pietras D; Gao Y; Zojer N; Ait-Tahar K; Banham AH; Pulford K; Rice J; Savelyeva N; Sahota SS
Leukemia; 2010 Nov; 24(11):1951-9. PubMed ID: 20861911
[TBL] [Abstract][Full Text] [Related]
25. In vivo transfection and/or cross-priming of dendritic cells following DNA and adenoviral immunizations for immunotherapy of cancer--changes in peripheral mononuclear subsets and intracellular IL-4 and IFN-gamma lymphokine profile.
Mincheff M; Altankova I; Zoubak S; Tchakarov S; Botev C; Petrov S; Krusteva E; Kurteva G; Kurtev P; Dimitrov V; Ilieva M; Georgiev G; Lissitchkov T; Chernozemski I; Meryman HT
Crit Rev Oncol Hematol; 2001; 39(1-2):125-32. PubMed ID: 11418309
[TBL] [Abstract][Full Text] [Related]
26. Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination.
Johnson LE; Olson BM; McNeel DG
J Immunother Cancer; 2017 Jul; 5(1):56. PubMed ID: 28716080
[TBL] [Abstract][Full Text] [Related]
27. A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice.
Xiang R; Primus FJ; Ruehlmann JM; Niethammer AG; Silletti S; Lode HN; Dolman CS; Gillies SD; Reisfeld RA
J Immunol; 2001 Oct; 167(8):4560-5. PubMed ID: 11591784
[TBL] [Abstract][Full Text] [Related]
28. Novel chemotactic-antigen DNA vaccine against cancer.
Zhang S; Zhang Y
Future Oncol; 2008 Apr; 4(2):299-303. PubMed ID: 18407741
[TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.
Conry RM; Curiel DT; Strong TV; Moore SE; Allen KO; Barlow DL; Shaw DR; LoBuglio AF
Clin Cancer Res; 2002 Sep; 8(9):2782-7. PubMed ID: 12231517
[TBL] [Abstract][Full Text] [Related]
30. DNA fusion vaccines induce epitope-specific cytotoxic CD8(+) T cells against human leukemia-associated minor histocompatibility antigens.
Rice J; Dunn S; Piper K; Buchan SL; Moss PA; Stevenson FK
Cancer Res; 2006 May; 66(10):5436-42. PubMed ID: 16707472
[TBL] [Abstract][Full Text] [Related]
31. DNA vaccines for cancer.
Boyd D; Hung CF; Wu TC
IDrugs; 2003 Dec; 6(12):1155-64. PubMed ID: 14666426
[TBL] [Abstract][Full Text] [Related]
32. DC-expressed MHC class I single-chain trimer-based vaccines prime cytotoxic T lymphocytes against exogenous but not endogenous antigens.
Ordaz ML; Larmonier N; Lybarger L
Cell Immunol; 2010; 262(2):141-9. PubMed ID: 20199770
[TBL] [Abstract][Full Text] [Related]
33. Heat shock protein 70/MAGE-3 fusion protein vaccine can enhance cellular and humoral immune responses to MAGE-3 in vivo.
Ma JH; Sui YF; Ye J; Huang YY; Li ZS; Chen GS; Qu P; Song HP; Zhang XM
Cancer Immunol Immunother; 2005 Sep; 54(9):907-14. PubMed ID: 15756604
[TBL] [Abstract][Full Text] [Related]
34. Design of Polyepitope DNA Vaccine against Breast Carcinoma Cells and Analysis of Its Expression in Dendritic Cells.
Nazarkina ZhK; Khar'kova MV; Antonets DV; Morozkin ES; Bazhan SI; Karpenko LI; Vlasov VV; Ilyichev AA; Laktionov PP
Bull Exp Biol Med; 2016 Feb; 160(4):486-90. PubMed ID: 26915653
[TBL] [Abstract][Full Text] [Related]
35. A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity.
Walters JN; Ferraro B; Duperret EK; Kraynyak KA; Chu J; Saint-Fleur A; Yan J; Levitsky H; Khan AS; Sardesai NY; Weiner DB
Mol Ther; 2017 Apr; 25(4):976-988. PubMed ID: 28237837
[TBL] [Abstract][Full Text] [Related]
36. Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use?
Strioga MM; Darinskas A; Pasukoniene V; Mlynska A; Ostapenko V; Schijns V
Vaccine; 2014 Jul; 32(32):4015-24. PubMed ID: 24837511
[TBL] [Abstract][Full Text] [Related]
37. Genetically modified tumour vaccines--where we are today.
Nawrocki S; Mackiewicz A
Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer vaccines: current status and future potential.
Doehn C; Böhmer T; Kausch I; Sommerauer M; Jocham D
BioDrugs; 2008; 22(2):71-84. PubMed ID: 18345705
[TBL] [Abstract][Full Text] [Related]
40. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]